Article

Controlled Correspondence with FDA – An Update

Controlled Correspondence with FDA – An Update

The US Food and Drug Administration (FDA) has recently finalized its guidance to generic drug manufacturers on how to seek drug development information through the controlled correspondence (CC) process. This guidance finalizes the draft guidance issued in Nov 2017 and replaces the finalized guidance issued in September 2015. This update on controlled correspondence with FDA …

Controlled Correspondence with FDA – An Update Read More »

nitrosamine-impurities

Nitrosamine Impurities: A Regulatory Perspective

In July 2018, the European medicines regulatory network became aware of the presence of nitrosamine impurities in an Active Pharmaceutical Ingredient (API). This was the first time that a nitrosamine impurity had been detected in a pharmaceutical drug. The unexpected delivery of these impurities resulted in voluntary product recalls on a mass scale and led …

Nitrosamine Impurities: A Regulatory Perspective Read More »